Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01258387 · ClinicalTrials.gov registry record · Phase 1
Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure
A Phase 1 study, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01258387 is a Phase 1 study that has completed, run by Acorda Therapeutics. The registered enrollment target is 40 participants.
The verdict
NCT01258387, a Phase 1 study, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Study to determine the safety, tolerability, pharmacokinetics and immunogenicity of single intravenous administrations of GGF2 in patients with heart failure.
Interventions
- OTHER Placebo
- DRUG Glial growth factor 2/ Neuregulin 1β3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01258387
The ClinicalTrials.gov registry entry for NCT01258387 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01258387 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01258387 about?
NCT01258387 is a clinical study titled "Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure". Study to determine the safety, tolerability, pharmacokinetics and immunogenicity of single intravenous administrations of GGF2 in patients with heart failure.
What is the current status of trial NCT01258387?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2010-12. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01258387?
The interventions under investigation include: Placebo (OTHER), Glial growth factor 2/ Neuregulin 1β3 (DRUG).
Who is sponsoring clinical trial NCT01258387?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.